Menu
home
about us
Investment Approach
Client Service Approach
Market Analysis Summary
Mission Statement
Value Proposition
Team Biographies
Firm ADV PDFs
Form CRS
Firm Brochure-Part 2A of Form ADV
Brochure Supplement Amit Stavinsky
Brochure Supplement Frank Parks
Brochure Supplement Dominick Savo
Brochure Supplement Richard Mason
Brochure Supplement Joe Estes
Brochure Supplement Jonathan Ezra
Statement Of Financial Strength
Job Opportunities
Tamar Advisors
Own Your Practice
Letter to Clients
member log-in
contact us
PRODUCTS
Fixed Income Portfolio (FIP)
FIP Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Total Asset Market (TAM)
TAM sm Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Total Asset Fund (TAF)
TAF sm Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Market Value Securities (MVS)
MVS Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Total Asset Value (TAV)
TAV Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Municipal Bonds
Taxable Bonds
Par, Premium, and Discount Bonds
Rating and Analyzing Bonds
Refunding & Pre-refunding
Bond Yields
Yield Curve
Secured Bonds
Mortgage Bonds
Unsecured Bonds
Debentures
Subordinated Debentures
Zero-Coupon Bonds
Convertible Bonds
High Yield Dividend Stocks
Independent Money Managers
Fees & Compensation
Corporate Cash Management
Fees & Compensation
Estate Planning
Financial Planning
Client Service Approach
Client's Responsibilities
Fees
Implementation
Legal Services
Termination
Professional Alliance Network
Client Service Approach
Client's Responsibilities
Fees
Implementation
Legal Services
Termination
MUNICIPAL BONDS
Municipal Bond Presentation
About Us
The Management
Global Asset Allocation Products
FIP Program
Classifying Municipal Bonds
Revenue Bonds
Credit Factors Affecting General Obligation Bonds
Credit Factors Affecting the Quality of Local Municipal Bonds
Analyzing the Credit Quality of General Obligation Bonds
Analyzing the Credit Quality of Revenue Municipal Bonds
What We Buy Currently
What We Normally Don’t Buy
Municipal Bonds – Unique Asset Class
Default Rates
Yield Difference
Turnkey Operation Platform
Advantages of Our Bid Wanted System
Advantages of Our Clearing System
Preferred Custodian Settlement
Advantages of Same-Day Allocation
TSL’s Turnkey Operation Platform
Sample Portfolio
Sample Portfolio Analysis
Classifying Municipal Bonds
Revenue Municipal Bonds
Types of Revenue Municipal Bonds
Industrial Development Revenue Bonds
Lease-back Bonds
Special Tax Bonds
NHA/PHA Bonds
Moral Obligation Bonds
Municipal Notes
TANs/RANs
BANs
CLNs/GANs
Variable Rate Bonds/Notes
Build America Bonds
Double-Barreled Bonds
Bond Index Components
Open-end-Closed-end-Indenture
Sinking Fund
Bond Contracts
Bond Indenture
Official Statement
Bond Issuance Process
Analyzing GO Bonds
Analyzing Revenue Bonds
Debt Ratios
General Price Analysis of Municipal Bonds
Liquidity
Interest Rate Risk
Credit Risk
Coupon Risk
Maturity Risk
Municipal Bond Insurance
Municipal Bonds Unique Asset Class
Default Rates
What We Buy Currently
What We Normally Don’t Buy
Turnkey Operation Platform
Advantages of Our Bid Wanted System
Advantages of Our Clearing System
Preferred Custodian Settlement
Advantages of Same Day Allocation
Traditional Broker/Dealer Execution Flow
TSL's Turnkey Operation Platform
INDEX FUNDS
Total Asset Fund (TAF)
TAF sm Program
Services, Fees and Compensation
Account Requirements
Client Information
Client Contact with Portfolio Manager(s)
Additional Information
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
EVENTS
FIP
Event Schedule
Municipal Bond Presentation
TAM
Event Schedule
Total Asset Market (TAM sm) Presentation
TAF
Event Schedule
Total Asset Fund (TAF sm) Presentation
MVS
Event Schedule
Market Value Securities (MVS sm) Presentation
Featured Event
Calendar of Events
Events History
Investing During Uncertain Times
Read FULL Seminar Here
Tax-Free Income Seminar
Bond Fund Seminar
RSVP-Signup Form
MARKET RESEARCH
Featured Quarterly Newsletter
Featured Articles
Contrarian Notes Blog
home
about us
Investment Approach
Client Service Approach
Market Analysis Summary
Mission Statement
Value Proposition
Team Biographies
Firm ADV PDFs
Form CRS
Firm Brochure-Part 2A of Form ADV
Brochure Supplement Amit Stavinsky
Brochure Supplement Frank Parks
Brochure Supplement Dominick Savo
Brochure Supplement Richard Mason
Brochure Supplement Joe Estes
Brochure Supplement Jonathan Ezra
Statement Of Financial Strength
Job Opportunities
Tamar Advisors
Own Your Practice
Letter to Clients
member log-in
contact us
PRODUCTS
Fixed Income Portfolio (FIP)
FIP Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Total Asset Market (TAM)
TAM sm Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Total Asset Fund (TAF)
TAF sm Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Market Value Securities (MVS)
MVS Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Total Asset Value (TAV)
TAV Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Municipal Bonds
Taxable Bonds
Par, Premium, and Discount Bonds
Rating and Analyzing Bonds
Refunding & Pre-refunding
Bond Yields
Yield Curve
Secured Bonds
Mortgage Bonds
Unsecured Bonds
Debentures
Subordinated Debentures
Zero-Coupon Bonds
Convertible Bonds
High Yield Dividend Stocks
Independent Money Managers
Fees & Compensation
Corporate Cash Management
Fees & Compensation
Estate Planning
Financial Planning
Client Service Approach
Client's Responsibilities
Fees
Implementation
Legal Services
Termination
Professional Alliance Network
Client Service Approach
Client's Responsibilities
Fees
Implementation
Legal Services
Termination
MUNICIPAL BONDS
Municipal Bond Presentation
About Us
The Management
Global Asset Allocation Products
FIP Program
Classifying Municipal Bonds
Revenue Bonds
Credit Factors Affecting General Obligation Bonds
Credit Factors Affecting the Quality of Local Municipal Bonds
Analyzing the Credit Quality of General Obligation Bonds
Analyzing the Credit Quality of Revenue Municipal Bonds
What We Normally Buy
What We Normally Don’t Buy
Municipal Bonds – Unique Asset Class
Default Rates
Yield Difference
Turnkey Operation Platform
Advantages of Our Bid Wanted System
Advantages of Our Clearing System
Preferred Custodian Settlement
Advantages of Same-Day Allocation
TSL’s Turnkey Operation Platform
Classifying Municipal Bonds
Revenue Municipal Bonds
Types of Revenue Municipal Bonds
Industrial Development Revenue Bonds
Lease-back Bonds
Special Tax Bonds
NHA/PHA Bonds
Moral Obligation Bonds
Municipal Notes
TANs/RANs
BANs
CLNs/GANs
Variable Rate Bonds/Notes
Build America Bonds
Double-Barreled Bonds
Bond Index Components
Open-end-Closed-end-Indenture
Sinking Fund
Bond Contracts
Bond Indenture
Official Statement
Bond Issuance Process
Analyzing GO Bonds
Analyzing Revenue Bonds
Debt Ratios
General Price Analysis of Municipal Bonds
Liquidity
Interest Rate Risk
Credit Risk
Coupon Risk
Maturity Risk
Municipal Bond Insurance
Municipal Bonds Unique Asset Class
Default Rates
What We Buy Currently
What We Normally Don’t Buy
Turnkey Operation Platform
Advantages of Our Bid Wanted System
Advantages of Our Clearing System
Preferred Custodian Settlement
Advantages of Same Day Allocation
Traditional Broker/Dealer Execution Flow
TSL's Turnkey Operation Platform
INDEX FUNDS
Total Asset Fund (TAF)
TAF® Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Additional Information
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
EVENTS
FIP
Event Schedule
TAM
Event Schedule
Total Asset Market (TAM sm) Presentation
TAF
Event Schedule
Total Asset Fund (TAF sm) Presentation
MVS
Event Schedule
Market Value Securities (MVS sm) Presentation
Featured Event
Calendar of Events
Events History
Investing During Uncertain Times
Read FULL Seminar Here
Tax-Free Income Seminar
Bond Fund Seminar
RSVP-Signup Form
MARKET RESEARCH
Featured Quarterly Newsletter
Featured Articles
Contrarian Notes Blog
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
GSK plc American Depositary Shares (Each representing two Ordinary Shares)
(NY:
GSK
)
51.69
UNCHANGED
Streaming Delayed Price
Updated: 7:00 PM EDT, Jul 31, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about GSK plc American Depositary Shares (Each representing two Ordinary Shares)
< Previous
1
2
3
4
5
6
7
8
9
...
45
46
Next >
GSK Leaps Into Buy Zone On Surprise Departure Of CEO Emma Walmsley
↗
September 29, 2025
Shares had broke out earlier this month, but have floundered at the lower boundary of the chart pattern.
Via
Investor's Business Daily
Amgen Expands US Manufacturing Network Amid New Tariff Policy
↗
September 26, 2025
Just when the Trump administration announced a 100% tariff on pharmaceuticals starting in October, Amgen Inc (NASDAQ: AMGN) announced a $650 million expansion of its U.S. manufacturing network.
Via
Benzinga
Topics
Government
World Trade
Trump's 100% Pharmaceutical Tariff: The $270 Billion Manufacturing War That Could Reshape Your Medicine Cabinet
↗
September 26, 2025
Trump’s sweeping 100% pharmaceutical tariff starting October 1 triggers massive $270 billion industry investment surge, creating clear stock market winners like Eli Lilly while foreign-de
Via
Benzinga
Topics
Government
World Trade
Robert F. Kennedy Jr. Faces Impeachment Push From Haley Stevens Over 'Health Care Chaos' And Rising Costs: 'Enough Is Enough'
↗
September 26, 2025
Rep. Haley Stevens (D-Mich.) announced that she will introduce articles of impeachment against Health and Human Services Secretary Robert F. Kennedy Jr.
Via
Benzinga
Kenvue Stock Hits Record Low As Trump Urges Pregnant Women To ‘Fight Like Hell’ Against Tylenol: Retail Stays Bullish
↗
September 22, 2025
Via
Stocktwits
Topics
Government
Wave Life Sciences Tumbled 19% Today, But Not Everyone’s Disappointed – Find Out Why
↗
September 03, 2025
Via
Stocktwits
Kenvue Bounces Off Record Low: A Deep Dive into its Rebound and Future Prospects
September 24, 2025
Kenvue (NYSE: KVUE), the consumer health giant spun off from Johnson & Johnson, has experienced a significant rebound in its stock price, climbing notably from a recent record low. This resurgence...
Via
MarketMinute
Topics
Government
Product Recall
Trump Advises Parents To Split Vaccines, Delay Hepatitis B Shots Until Age 12: 'This Is Based On What I Feel'
↗
September 22, 2025
President Donald Trump on Monday offered advice on childhood vaccination schedules, encouraging parents to split up certain immunizations and delay certain others, in sharp contradiction to current...
Via
Benzinga
Topics
Government
Elizabeth Warren Says Measles Can Hit Record Highs, Slams RFK Jr.'s CDC Panel For Delaying Vaccine: 'How Does That Keep Our Kids Safe?'
↗
September 18, 2025
Sen. Elizabeth Warren (D-Mass.) on Thursday criticized the Centers for Disease Control and Prevention's vaccine advisory panel following its controversial vote to delay the combined measles, mumps,...
Via
Benzinga
What's Driving the Market Sentiment Around GSK?
↗
September 03, 2025
Via
Benzinga
GSK Secures UK Approval For First New Oral Antibiotic In 30 Years To Treat Resistant Urinary Tract Infections
↗
August 27, 2025
Via
Stocktwits
GSK To Pour $30 Billion Into US R&D, Manufacturing Over Five Years
↗
September 17, 2025
GSK will invest $30 billion in U.S. R&D and manufacturing, including a new biologics factory, AI upgrades, and expanded drug and device capabilities.
Via
Benzinga
Topics
Artificial Intelligence
Dow Futures Stall Ahead Of Fed’s Interest Rate Decision Today: WDAY, MSFT, GOOGL, NVDA Among Stocks To Watch
↗
September 17, 2025
While Dow Jones futures were up 0.03% at the time of writing, the S&P 500 futures fell 0.07%.
Via
Stocktwits
Topics
ETFs
Economy
Government
GSK Stock Climbs After-Hours On $30B US Investment Pledge As Trump Pressures Big Pharma To Build In America
↗
September 16, 2025
The plan includes $1.2 billion for a new biologics factory in Upper Merion, Pennsylvania, along with AI upgrades and expanded drug production across existing U.S. sites.
Via
Stocktwits
Topics
Artificial Intelligence
Government
World Trade
Robert Kennedy Jr. Packs CDC Panel With Vaccine Skeptics Ahead of Key Vote On COVID-19 Shots
↗
September 15, 2025
Health and Human Services Secretary Robert F. Kennedy Jr. has added five new members to the Centers for Disease Control and Prevention's (CDC) Advisory Committee on Immunization Practices, just days...
Via
Benzinga
Price Over Earnings Overview: GSK
↗
August 27, 2025
Via
Benzinga
Recent Report Shows That Rep. Robert Aderholt Sold Up to $15K Worth of GSK Stock
↗
September 11, 2025
Via
Benzinga
Robert F. Kennedy Took Fire From Both Republicans And Democrats Over Vaccine Overhauls: GOP Senators Defend Trump's Operation Warp Speed
↗
September 05, 2025
Secretary for Health and Human Services, Robert F. Kennedy Jr., faced bipartisan backlash during a combative Senate hearing on Thursday, as both Republicans and Democrats criticized his controversial...
Via
Benzinga
Topics
Government
Robert F. Kennedy Jr.'s Vaccine Shake-Up Sparks Coast-To-Coast Divide: West Coast Creates Health Alliance, Florida Rolls Back Requirements
↗
September 04, 2025
California, Oregon and Washington form regional vaccine alliance to counter federal guidance under Robert F. Kennedy Jr. as Florida eliminates state mandates.
Via
Benzinga
Florida Chooses 'Medical Freedom' As State Plans To End Vaccine Mandates, Even For Schools: Experts Warn Of 'Major Disaster'
↗
September 04, 2025
Florida plans to end all statewide vaccine mandates, even those required for school attendance, framing the move as a defense of individual liberties, which has since received pushback from public...
Via
Benzinga
Why Is GSK Partner Wave Life Sciences Stock Trading Lower On Wednesday?
↗
September 03, 2025
Wave Life Sciences shares early WVE-006 trial results in alpha-1 antitrypsin deficiency, reporting durable protein production and favorable safety.
Via
Benzinga
Upstream's New Sinus Treatment Cuts Need For Surgery, Early Trial Finds
↗
September 02, 2025
Upstream Bio's Phase 2 trial of verekitug in chronic rhinosinusitis met all endpoints, showing reduced nasal polyps, congestion, and need for surgery.
Via
Benzinga
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of GSK plc – GSK
September 02, 2025
From
Pomerantz LLP
Via
GlobeNewswire
Bernie Sanders Demands Health Secretary RFK Jr.'s Resignation As CDC Leadership Crisis Deepens
↗
August 30, 2025
Senator Bernie Sanders called for HHS Secretary RFK Jr.'s resignation over his anti-vaccine policies, ousting of CDC Director Susan Monarez.
Via
Benzinga
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of GSK plc – GSK
August 29, 2025
From
Pomerantz LLP
Via
GlobeNewswire
Elizabeth Warren Slams Trump's CDC Purge: Calls Out RFK Jr's Statements On Measles Vaccines — 'These Fools Can't Be Trusted With Your Health'
↗
August 29, 2025
Sen. Elizabeth Warren (D-Mass.) is sounding the alarm on President Donald Trump's attempts at overhauling leadership at the Centers for Disease Control and Prevention, warning of risks to public...
Via
Benzinga
Topics
Government
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of GSK plc – GSK
August 21, 2025
From
Pomerantz LLP
Via
GlobeNewswire
Dynavax Says Investigational Shingles Vaccine At Par With GSK's Vaccine In Early-Stage Study
↗
August 21, 2025
Dynavax's Z-1018 shingles vaccine matched Shingrix in immune response with fewer side effects, advancing to Phase 2 in older adults in 2025.
Via
Benzinga
CVS Health Declines To Add Gilead's Steeply Priced New HIV Prevention Drug To Its Plans
↗
August 21, 2025
CVS rejected coverage of Gilead's new HIV prevention drug Yeztugo, citing regulatory and financial factors, while facing nearly $290 million in Medicare overcharge penalties.
Via
Benzinga
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of GSK plc – GSK
August 17, 2025
From
Pomerantz LLP
Via
GlobeNewswire
< Previous
1
2
3
4
5
6
7
8
9
...
45
46
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.